Welcome to our dedicated page for Mereo Biopharma SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mereo BioPharma Group plc filings document a U.K. clinical-stage biopharmaceutical issuer whose Nasdaq-listed ADSs represent ordinary shares. Recent Form 8-K reports furnish quarterly and annual financial results, rare-disease pipeline updates, conference presentation materials, cash runway disclosures, and clinical-program announcements for setrusumab, alvelestat, and related partnered assets.
The filing record also covers proxy governance, executive compensation and equity-award disclosures, board composition matters, ADS and ordinary-share listing information, and Nasdaq continued-listing compliance notices. These documents frame Mereo's capital structure, governance practices, material events, and development-stage public-company reporting.
Mereo BioPharma Group plc ownership disclosure: EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman jointly report beneficial ownership on an amendment to Schedule 13G/A. The filing shows EcoR1 and Mr. Nodelman each report shared voting and dispositive power over 66,844,275 Ordinary Shares (representing 8.4% of the class). The Qualified Fund reports shared voting and dispositive power over 62,644,610 Ordinary Shares (representing 7.8%).
The filing states these Ordinary Shares are held through 13,368,855 American Depositary Shares (each ADS = 5 Ordinary Shares) and that the percentage calculations use 798,078,829 Ordinary Shares outstanding as of March 18, 2026 as reported in the issuer's Form 10-K for the fiscal year ended December 31, 2025. The reporting persons disclaim group membership and assert the holdings were not acquired to change control.
Mereo BioPharma Group plc ownership filing shows Bank of America Corporation reports beneficial ownership of 40,976,460 ordinary shares, representing 5.1% of the class. The calculation cites 798,078,829 shares outstanding as of March 18, 2026 from the issuer's Form 10-K. The filing states that the reported holdings reflect shared voting and dispositive power across Bank of America and certain wholly owned subsidiaries.
Mereo BioPharma Group plc reported the results of its 2026 Annual General Meeting, where all resolutions passed. Shareholder turnout was high, with 436,766,255 ordinary shares represented in person or by proxy.
Shareholders adopted the annual report and accounts for the year ended December 31, 2025, with 98.29% of votes cast in favor, and re-appointed PricewaterhouseCoopers LLP as auditors with 98.59% support. The Audit and Risk Committee was authorized to determine PwC’s remuneration.
Investors approved the directors’ remuneration report with 93.35% support and the directors’ remuneration policy, effective after the AGM, with 91.74% support. The compensation of named executive officers received 91.71% advisory approval. Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz were each re-elected as directors, receiving around 94% of votes cast.
Shareholders also authorized the directors to allot shares and grant rights to subscribe or convert up to a maximum nominal amount of £3,591,354.73, and to do so on a non-pre-emptive basis, both authorities running until June 30, 2029. These replace earlier share issuance authorities to the extent not already used.
Mereo BioPharma Group plc filed an amended report to correct a technical item tag and reiterated its first quarter 2026 results and clinical updates. The company reported a net loss of $6.7 million for the quarter, improving from $12.9 million a year earlier, as operating loss narrowed and foreign currency gains increased.
Research and development expenses rose to $4.7 million, mainly from higher setrusumab costs, while general and administrative expenses fell to $4.0 million driven by ADR reimbursement and lower pre-commercial spending. Cash and cash equivalents were $36.2 million as of March 31, 2026, which the company expects to fund operations into mid-2027.
Clinically, neither of the two global Phase 3 studies of setrusumab in osteogenesis imperfecta met their primary fracture-rate endpoints, though both achieved strong results on key secondary measures such as bone mineral density and vertebral fractures. Mereo and partner Ultragenyx have started discussions with regulators on a potential pediatric path. Mereo is also preparing alvelestat for a single Phase 3 trial in AATD lung disease and expects its partner āshibio to start a Phase 2 vantictumab trial in ADO2 in the second half of 2026.
Mereo BioPharma Group plc reported first quarter 2026 results and updates on its rare disease pipeline. For the quarter ended March 31, 2026, net loss narrowed to $6.7 million from $12.9 million a year earlier, helped by lower general and administrative expenses of $4.0 million versus $7.3 million. Research and development spending rose to $4.7 million from $3.9 million, mainly from higher setrusumab costs.
Cash and cash equivalents were $36.2 million as of March 31, 2026, compared with $41.0 million at December 31, 2025, and the company reiterates that this is expected to fund operations into mid-2027. Setrusumab’s two Phase 3 studies in osteogenesis imperfecta did not reach their primary fracture endpoints but showed strong improvements in bone mineral density, vertebral fractures and patient-reported outcomes, with a safety profile consistent with prior studies. Mereo and partner Ultragenyx have begun discussions with regulators on a potential pediatric path.
Mereo is seeking a partner to run a single Phase 3 alvelestat trial in approximately 220 AATD-LD patients over 18 months and expects vantictumab partner āshibio to start a Phase 2 trial in ADO2 in the second half of 2026.
Mereo BioPharma Group plc has called its 2026 annual general meeting for May 14, 2026 in London. Shareholders are asked to adopt the U.K. statutory annual report and accounts for 2025, re-appoint PricewaterhouseCoopers LLP as auditor and approve the auditors’ 2026 remuneration.
Advisory votes will cover the U.K. directors’ remuneration report, an updated three‑year directors’ remuneration policy, and 2025 compensation for named executive officers. Shareholders will also vote on the re‑election of Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz to the board.
The board seeks authority to allot shares or grant rights over shares up to a maximum aggregate nominal amount of £3,591,354.73 and to disapply statutory pre‑emption rights on the same nominal amount, both running until June 30, 2029. The company reports 798,078,829 ordinary shares issued and outstanding as of April 7, 2026.
Mereo BioPharma Group plc is convening its 2026 Annual General Meeting on May 14, 2026 to ask shareholders to approve eleven resolutions, including authority to allot shares and disapply pre-emption rights up to a maximum nominal amount of £3,591,354.73 expiring on June 30, 2029.
The meeting materials include the Company’s U.K. statutory annual report and accounts for the year ended December 31, 2025, re-appointment of PwC as auditor, approval of remuneration-related proposals, re-election of three directors, and references a Form S-3 shelf registration effective May 22, 2024 permitting ADS offerings up to $175 million. Shares outstanding were 798,078,829 as of April 7, 2026.
Mereo BioPharma Group plc reported that Dr. Annalisa Jenkins has informed the company she will not stand for re-election to its Board of Directors at the 2026 annual general meeting of shareholders scheduled for May 14, 2026.
She will continue to serve as a director until her current term expires immediately prior to that meeting. The company stated that Dr. Jenkins’ decision is not due to any disagreement with the company or the board regarding operations, policies, or practices, indicating a planned transition rather than a dispute-driven departure.